• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>DRS

DRS

  1. All
  2. 3rd Party
  3. Investing
  1. L3 Selected by Airbus to Provide and Integrate New Fixed and Deployable Flight Recorders for Commercial Jets

    L3 Selected by Airbus to Provide and Integrate New Fixed and Deployable Flight Recorders for Commercial Jets

  2. Repare Therapeutics Raises US$68 Million Series A

    Repare Therapeutics Raises US$68 Million Series A

  3. GI Dynamics Announces Additional Members to Its Scientific Advisory Board

    GI Dynamics Announces Additional Members to Its Scientific Advisory Board

  4. KBI Biopharma Acquires Alliance Protein Laboratories, Expands Biophysical Characterization Capabilities

    KBI Biopharma Acquires Alliance Protein Laboratories, Expands Biophysical Characterization Capabilities

  5. CARMA Therapeutics Closes Initial Funding to Advance Chimeric Antigen Receptor Macrophages (CARMA) to Treat Solid Tumors

    CARMA Therapeutics Closes Initial Funding to Advance Chimeric Antigen Receptor Macrophages (CARMA) to Treat Solid Tumors

  6. Global Rugged Handheld Devices Market 2017-2021: Growing Preference for Bigger Screen Handheld Mobile Computers in Manufacturing, Healthcare, and Logistics - Research and Markets

    Global Rugged Handheld Devices Market 2017-2021: Growing Preference for Bigger Screen Handheld Mobile Computers in Manufacturing, Healthcare, and Logistics - Research and Markets

  7. Ixcela Announces Partnership with ORACLE TEAM USA to Improve Athletes’ Internal Health and Performance

    Ixcela Announces Partnership with ORACLE TEAM USA to Improve Athletes’ Internal Health and Performance

  8. joimax® Elevates Its Presence across Europe and Asia

    joimax® Elevates Its Presence across Europe and Asia

  9. OMEICOS Secures Continued BMBF Support with New €1.7M Research Grant to Advance its Novel Approach to Treat Cardiovascular Diseases

    OMEICOS Secures Continued BMBF Support with New €1.7M Research Grant to Advance its Novel Approach to Treat Cardiovascular Diseases

  10. Cagent Vascular Completes Enrollment of PRELUDE Study Using Serranator Device

    Cagent Vascular Completes Enrollment of PRELUDE Study Using Serranator Device

12

©2017 Morningstar Advisor. All right reserved.